Skip to content
Back to meeting Original
METCrusaders· @metcrusaders · X·· 3 days agoScore45
Body · original

Agree, @dplanchard, and we think access is the piece patients will feel most. A drug that works doesn’t help anyone who can’t get tested or can’t get it prescribed, so MET testing at progression needs to become routine now, before an FDA decision. #lcsm #ESMO26

12 views · 1 like · 0 reposts · 0 replies

引用@
A major new milestone post-osimertinib! Totally agree with Natasha: a new therapeutic standard, MET testing for all our #EGFRm pts with disease progression post-Osi, and access to Osi + Savolitinib (now the most difficult step for our patients upon our return post-#ESMO26)...
在 X 查看被引用的帖子

Source: METCrusaders · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.